EC Clinical and Medical Case Reports

Research Article Volume 7 Issue 8 - 2024

SAPS 3, SOFA, QSOFA, PORT and 4C Mortality Score as Predictors of Mortality in Patients with COVID 19 in Mexico

Jose Ivan Rodriguez de Molina Serrano1*, Adriana Sarai Galindo Rodriguez2, Jorge de Santiago Camarillo3, Suridday Trejo Roldán3, Isela Denise Peña Chavez4, Adalberto Peña Chavez5 and Fabiola Maely Gonzalez Ortiz6

1Head of the Intensive Care Unit of the Clinica Mexico, Head of the Respiratory Diseases Unit of the Clinica México and Assigned Physician of the Intensive Care Unit and Leader of the COVID Unit of the General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico

2Associate Researcher, Assistant Physician in the Intensive Care Unit of the Mexico Clinic and General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico

3Associate Researcher, General Physician, Assistant Physician in the Intensive Care Unit of the Mexico Clinic and General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico

4Associate Researcher, Internal Medicine, Assistant Physician in the Intensive Care Unit of Clinica Mexico, Mexico

5Associate Researcher, General Surgery, Advanced Laparoscopy, Medical Director Clínica México, Mexico

6HOHY PTE LTD, Singapore

*Corresponding Author: Jose Ivan Rodriguez de Molina Serrano, Head of the Intensive Care Unit of the Clinica Mexico, Head of the Respiratory Diseases Unit of the Clinica México and Assigned Physician of the Intensive Care Unit and Leader of the COVID Unit of the General Hospital of Zone 11 IMSS Piedras Negras Coahuila, Mexico.
Received: July 02, 2024; Published: July 30, 2024




Introduction: At the end of 2019, a new coronavirus (2019-nCoV) was identified as the cause of pneumonia in the city of Wuhan, in the province of Hubei, China. In February 2020, the WHO designated this disease as COVID 19 (Coronavirus Disease 2019) and its etiological agent was named as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). In Mexico until June 23, 2021 there were 2,487,172 confirmed cases, 434,533 suspected cases, with 231,184 deaths. Regarding the confirmed cases, 18.51% required hospitalization and 81.29% only isolation at home. In the city of Piedras Negras, Coahuila, 6,701 confirmed cases were reported with 424 deaths and 43 active cases; of these, 10.87% required hospitalization and 89.13% only isolation at home. The markers that have been related to an increase in disease severity and mortality are Pro-B natriuretic peptide, high sensitivity troponin I, creatine phosphokinase MB fraction, interleukin-6, D dimer, C-reactive protein, sequential organ failure assessment (SOFA), lactate dehydrogenase, alanine-amino transferase, aspartate-amino transferase, hypoalbuminemia, leukocytosis, neutrophilia, lymphopenia, procalcitonin.

Objective of the Study: E valuate the ability to predict mortality, in COVID 19 patients treated at the Respiratory Unit at Clinica México, of the SAPS 3, SOFA, qSOFA, PORT and 4C Mortality Score.

Methods: Prospective, observational, longitudinal study from April 8, 2020 to May 21, 2021, patients with COVID 19. Severity scales and demographic data were recorded in the first 24 hours of admission. The statistical analysis was correlation and calculation of AUC for mortality with p < 0.05. Informed consent was obtained.

Results: 58 patients were admitted to the study, age 51.05 years, male 74.1%. Hospital mortality was 20.7%. The cause of admission was classified as Threat of organic failure 53.45%, Invasive Mechanical Ventilation and/or non- invasive since admission 43.10%. The average days of stay was 11.12, the average hours of invasive mechanical ventilation were 141.39, the average hours of non-invasive mechanical ventilation were 50.79. The predictive capacity for mortality was statistically significant for the four scales SAPS3 AUC = 0.84, SOFA AUC = 0.99, qSOFA AUC = 0.89, PORT AUC = 0.73 and 4C Mortality Score AUC = 0.81.

Conclusion: The scales SAPS 3, SOFA, qSOFA, PORT and 4C Mortality Score are useful as tools for predicting mortality in Mexican COVID 19 patients. The use of these tools can improve the profiling of patients to better distribute care resources, which are limited in most centers in our country. It is necessary to evaluate these results in a larger cohort and in other units with different characteristics from ours.

 Keywords: COVID19; Mexico; Mortality; Mechanical Ventilation; Pneumonia; Prognosis

  1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020 (2020).
  2. Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals (2020).
  3. Lineamiento clinico COVID-19 CCINSHAE. Secretaria de Salud Gobierno de México 14 de febrero.
  4. World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance (2020).
  5. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. “[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]”. Zhonghua Liu Xing Bing Xue Za Zhi2 (2020): 145-151.
  6. Gorbalenya Susan., et al. “The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nature Microbiology 4 (2020): 536-544.
  7. Neeltje van Doremalen., et al. “Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1”. New England Journal of Medicine 16 (2020): 1564-1567.
  8. Qun Li., et al. “Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia”. New England Journal of Medicine 13 (2020): 1199-1207.
  9. Xi He., et al. “Temporal dynamics in viral shedding and transmissibility of COVID-19”. Nature Medicine 5 (2020): 672-675.
  10. Moor J., et al. “Cytokine release syndrome in severe COVID-19”. Science6490 (2020): 473-474.
  11. Waleed Al., et al. “Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)”. Intensive Care Medicine5 (2020): 854-887.
  12. Joshua P Metlay., et al. “Diagnosis and treatment of adults with community-acquired pneumonia an official clinical practice guideline of the American thoracic society and infectious diseases society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
  13. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. Journal of the American Medical Association 11 (2020): 1061-1069.
  14. Potere N., et al. “Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis”. Critical Care 1 (2020): 389.
  15. Islam N., et al. “Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries”. British Medical Journal 373 (2021): n1137.
  16. Qin JJ., et al. “Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19”. Hypertension4 (2020): 1104-1112.
  17. Cummings MJ., et al. “Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study”. Lancet 10239 (2020): 1763-1770.
  18. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.
  19. Weber S., et al. “Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study”. Gut10 (2021): 1925-1932.
  20. Wu S., et al. “Identification and validation of a novel clinical signature to predict the prognosis in confirmed coronavirus disease 2019 patients”. Clinical Infectious Diseases 12 (2020): 3154-3162.
  21. Clift AK., et al. “Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study”. British Medical Journal 371 (2020): m3731.
  22. Berenguer J., et al. “Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score”. Thorax9 (2021): 920-929.
  23. Vincent JL., et al. “Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine”. Critical Care Medicine 11 (1998): 1793-1800.
  24. Freund Y., et al. “Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department”. Journal of the American Medical Association3 (2017): 301-308.
  25. Moreno RP., et al. “SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission”. Intensive Care Medicine 10 (2005): 1345-1355.
  26. Knight SR., et al. “Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score”. British Medical Journal 370 (2020): m3339.
  27. Metlay JP., et al. “Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American thoracic society and infectious diseases society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
  28. Rodriguez de Molina JI., et al. “Resúmenes de Trabajos Libres”. Medicina crítica 5 (2020): 302-310.
  29. Galicia GC., et al. “Asociación de ferritina con deterioro ventilatorio y mortalidad debido a COVID-19 en terapia intensive”. Medicina crítica 3 (2021): 121-129.
  30. Montalvo AM and González LCA. “Índice neutrófilos/linfocitos: un predictor de mortalidad en paciente con infección por SARS-CoV-2”. Medicina crítica 3 (2021): 130-135.
  31. Artero A., et al. “Severity scores in COVID-19 pneumonia: a multicenter, retrospective, cohort study”. Journal of General Internal Medicine 5 (2021): 1338-1345.
  32. Kurtz P., et al. “SAPS-3 performance for hospital mortality prediction in 30,571 patients with COVID-19 admitted to ICUs in Brazil”. Intensive Care Medicine 9 (2021): 1047-1049.
  33. Jiang Y., et al. “Risk factors associated with 28-day all-cause mortality in older severe COVID-19 patients in Wuhan, China: a retrospective observational study”. Scientific Reports 1 (2020): 22369.

Jose Ivan Rodriguez de Molina Serrano., et al. "SAPS 3, SOFA, QSOFA, PORT and 4C Mortality Score as Predictors of Mortality in Patients with COVID 19 in Mexico." EC Clinical and Medical Case Reports 7.8 (2024): 01-12.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net